HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice.

Abstract
The identification of a dysferlin-deficient animal model that accurately displays both the physiological and behavior aspects of human dysferlinopathy is critical for the evaluation of potential therapeutics. Disease progression in dysferlin-deficient mice is relatively mild, compared to the debilitating human disease which manifests in impairment of particular motor functions. Since there are no other known models of dysferlinopathy in other species, locomotor proficiency and muscular anatomy through MRI (both lower leg and hip region) were evaluated in dysferlin-deficient B6.A-Dysfprmd /GeneJ (Bla/J) mice to define disease parameters for therapeutic assessment. Despite the early and progressive gluteal muscle dystrophy and significant fatty acid accumulation, the emergence of significant motor function deficits was apparent at approximately 1 year of age for standard motor challenges including the rotarod, a marble bury test, grip strength, and swimming speed. Earlier observations of decreased performance for Bla/J mice were evident during extended monitoring of overall exploration and rearing activity. Comprehensive treadmill gait analyses of the Bla/J model indicated significant differences in paw placement angles and stance in relation to speed and platform slope. At 18 months of age, there was no significant difference in the life expectancy of Bla/J mice compared to wild type. Consistent with progressive volume loss and fatty acid accumulation in the hip region observed by MRI, mass measurement of individual muscles confirmed gluteal and psoas muscles were the only muscles demonstrating a significant decrease in muscle mass, which is analogous to hip-girdle weakness observed in human dysferlin-deficient patients. Collectively, this longitudinal analysis identifies consistent disease parameters that can be indicators of efficacy in studies developing treatments for human dysferlin deficiency.
AuthorsNadia Nagy, Randal J Nonneman, Telmo Llanga, Catherine F Dial, Natallia V Riddick, Tom Hampton, Sheryl S Moy, Kimmo K Lehtimäki, Toni Ahtoniemi, Jukka Puoliväli, Hillarie Windish, Douglas Albrecht, Isabelle Richard, Matthew L Hirsch
JournalPhysiological reports (Physiol Rep) Vol. 5 Issue 6 (Mar 2017) ISSN: 2051-817X [Electronic] United States
PMID28320887 (Publication Type: Journal Article)
Copyright© 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
Chemical References
  • Dysf protein, mouse
  • Dysferlin
Topics
  • Animals
  • Disease Models, Animal
  • Dysferlin (genetics)
  • Female
  • Gait (physiology)
  • Hip (diagnostic imaging)
  • Male
  • Mice
  • Mice, Knockout
  • Motor Activity (physiology)
  • Muscle, Skeletal (diagnostic imaging, physiopathology)
  • Muscular Dystrophies (diagnostic imaging, genetics, physiopathology)
  • Muscular Dystrophies, Limb-Girdle (diagnostic imaging, genetics, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: